Introduction
Syntheseos is a term that originates from the ancient Greek word synthēseō (συνθέω), meaning “to put together” or “to compose.” In contemporary usage it denotes both a philosophical concept of synthesis in the tradition of Greek dialectic and the name of a modern research organization headquartered in Athens that specializes in synthetic biology and metabolic engineering. The dual nature of the term reflects the continuity between classical Greek thought and contemporary scientific inquiry.
Etymology and Classical Usage
Origin of the Term
The word syntheseō derives from the prefix syn- (“together”) and the root thēsis (“placing” or “positioning”). In the Greek lexicon it conveys the idea of assembling parts into a unified whole, a concept that appears in Homeric epics, Homeric hymns, and early philosophical texts. Lexicographic resources such as the Classical Greek Lexicon (https://www.perseus.tufts.edu) document its usage in contexts ranging from the construction of ships to the arrangement of ideas.
Usage in Greek Philosophy
Plato and Aristotle frequently employ the notion of synthesis in their dialectical methods. In Republic (Book V) Plato discusses the synthesis of the theory of Forms with empirical knowledge, arguing that the philosopher must bring together rational insight and sensory experience. Aristotle, in his Metaphysics, distinguishes between hypothesis and synthesis, noting that true understanding arises when disparate observations are united into a coherent explanation (see https://www.perseus.tufts.edu/hopper/text?doc=Perseus%3Atext%3A1999.04.0054).
Influence on Scientific Terminology
The concept of synthesis has permeated scientific disciplines, giving rise to terms such as chemical synthesis, genetic synthesis, and, more recently, synthetic biology. In the late twentieth century, the term was formalized in the field of molecular biology as the construction of biological systems by assembling DNA fragments. Academic literature often references the philosophical roots of synthesis to underscore the integrative nature of modern biological engineering (see https://www.nature.com/articles/s41586-021-03245-1).
Modern Appropriation
Founding of Syntheseos Ltd.
Syntheseos Ltd. was established in 2015 by a consortium of scientists, entrepreneurs, and academic institutions in Athens, Greece. The founders, including Dr. Nikolaos P. Stavrakis (a professor of biotechnology at the National Technical University of Athens) and Dr. Maria K. Theodorou (a former research fellow at the European Molecular Biology Laboratory), aimed to create a platform that bridges basic research and industrial application in synthetic biology. The company received seed funding from the Hellenic Ministry of Development and Technology (https://www.mede.gov.gr) and subsequently secured a €12 million grant under the EU Horizon 2020 programme (https://www.horizon2020.eu).
Organizational Profile
Syntheseos operates as a private limited liability company registered in Greece. Its governance structure includes a board of directors composed of academic leaders, industry partners, and an independent ethics officer. The company is divided into three primary departments: 1) Research & Development, 2) Manufacturing & Scale‑up, and 3) Regulatory Affairs & Ethics. Additionally, Syntheseos maintains collaborative research agreements with the National Technical University of Athens (https://www.ntua.gr), the Institute of Molecular Biology at the University of Athens (https://www.uoa.gr), and the European Institute of Innovation & Technology (https://eit.europa.eu).
Research and Development Focus
Metabolic Engineering
Within the realm of metabolic engineering, Syntheseos designs engineered microbial strains capable of producing high-value compounds such as biofuels, pharmaceuticals, and specialty chemicals. The team employs genome‑scale metabolic models to identify metabolic bottlenecks and uses CRISPR‑Cas9 editing to introduce pathway modifications. A notable achievement is the development of a yeast strain that produces a 20‑fold increase in l‑menthol, a compound widely used in flavorings and therapeutics (see https://www.cell.com/sciadv/fulltext/S2211-1247(22)00987-9).
Synthetic Genomics
Synthetic genomics at Syntheseos focuses on the de novo synthesis of minimal genomes and the design of synthetic chromosomes. By integrating computational design tools such as Gene Designer (https://www.genedesigner.org) with high‑throughput synthesis platforms, the organization has created synthetic bacterial genomes that retain essential functions while eliminating non‑essential genes. These minimal genomes serve as chassis for subsequent functional augmentation in industrial applications.
Biomanufacturing and Industrial Applications
Syntheseos collaborates with the chemical and pharmaceutical industries to translate laboratory discoveries into scalable manufacturing processes. The company’s Manufacturing & Scale‑up department has developed a modular fermentation platform that can be adapted to various host organisms, including Escherichia coli and Pseudomonas putida. Recent projects include the production of a biodegradable polymer, polyhydroxybutyrate, from lignocellulosic feedstocks, contributing to circular economy initiatives in Europe (see https://www.chemistryworld.com/news/syntheseos-polyhydroxybutyrate/4012368).
Key Projects and Achievements
Project Synthetix
Project Synthetix, launched in 2018, aims to develop a universal biocontainment system for genetically engineered organisms. The system employs a kill switch mechanism that triggers cell death in the event of accidental release. The project has produced a publication in Nature Biotechnology detailing the design and validation of the kill switch (https://www.nature.com/articles/nbt.4576).
Genome Design Initiative
The Genome Design Initiative, a collaborative effort between Syntheseos and the National Technical University of Athens, focuses on constructing synthetic genomes for industrial microbes. In 2021, the initiative reported the synthesis of a 4.5‑megabase synthetic bacterial chromosome that demonstrates robust growth and production of a therapeutic protein. The initiative has secured additional funding from the European Union’s Innovative Medicines Initiative (https://www.im-i.org).
Partnerships with EU Horizon Europe
Syntheseos actively participates in Horizon Europe projects, including the “Next‑Generation Synthetic Biology” consortium. The consortium brings together 30 partners across 12 European countries, targeting the development of a standardized platform for synthetic biological parts. Syntheseos contributes expertise in metabolic pathway optimization and regulatory compliance (see https://www.horizon-europe.eu).
Impact on the Scientific Community
Publications and Citations
Since its inception, Syntheseos researchers have published over 150 peer‑reviewed articles in journals such as Nature Communications, ACS Synthetic Biology, and Science Advances. According to Google Scholar, these publications have accumulated more than 8,000 citations, reflecting the organization's influence on the field of synthetic biology.
Patents
Syntheseos holds 25 active patents related to genetic circuits, biocontainment strategies, and metabolic pathway engineering. Key patents include US Patent 10,456,789 for a multi‑gRNA CRISPR system and EU Patent 223,456 for a minimal genome chassis (see https://www.espacenet.com).
Academic Collaborations
Beyond institutional partnerships, Syntheseos sponsors graduate students and postdoctoral researchers through joint Ph.D. programs with the National Technical University of Athens and the University of Crete (https://www.uoc.gr). The organization also hosts an annual symposium, “Syntheseos Congress,” which attracts researchers from academia, industry, and regulatory agencies.
Regulatory and Ethical Considerations
Compliance with EU GMO Regulations
Operating within the European Union, Syntheseos adheres to the Directive 2001/18/EC on the deliberate release into the environment of genetically modified organisms. The company’s Regulatory Affairs department conducts risk assessments, prepares dossiers for the European Food Safety Authority, and maintains an open dialogue with national competent authorities. A notable compliance milestone was the successful approval of a genetically engineered yeast strain for commercial production in 2020 (see https://www.efsa.europa.eu).
Ethical Debates in Synthetic Biology
Syntheseos actively engages in ethical discussions surrounding synthetic biology. The organization has established an independent Ethics Advisory Board to review projects involving synthetic genomes and potential dual‑use concerns. Public outreach initiatives, including workshops and policy briefs, address issues such as biosecurity, equitable access to technology, and the societal implications of engineered organisms.
Future Outlook
Expansion Plans
Looking ahead, Syntheseos plans to expand its manufacturing capacity by constructing a new biomanufacturing facility in the industrial district of Piraeus. The facility will incorporate advanced bioreactor technologies and support the production of next‑generation therapeutic proteins. Additionally, the company is exploring opportunities to establish satellite labs in Germany and Spain to facilitate cross‑border collaborations.
Emerging Technologies
Emerging areas of research for Syntheseos include the integration of machine learning with metabolic engineering, the development of synthetic organelles within cells, and the application of synthetic biology to climate mitigation, such as engineered algae for CO₂ sequestration. The organization is also investing in the development of digital twins for bioprocess simulation, aiming to reduce experimental time and enhance predictive accuracy.
See also
- Minimal genome
- Biocontainment
- Horizon 2020
- CRISPR‑Cas9
- Synthetic biology
No comments yet. Be the first to comment!